Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

r extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C- IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1- 800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; legal matters, including the ultimate outcome of the FTC litigation or the amount of time it will take for the FTC litigation to be resolved; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 02, 2014 Myriant Corporation, a ... of a distribution agreement with Azelis Group, a ... Myriant’s bio-succinic acid in the Nordics, Benelux, France, ... customers in the industrial and base chemicals markets. ... offers a far-reaching chemical portfolio with extensive distribution ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The inventors ... cure for chronic tinnitus are seeking support for development ... the Indiegogo platform ( http://igg.me/at/tinaway ), was launched on ... a therapeutic ‘mHealth’ app and is based on ten ... a team of biomedical and software engineers, Dr. Ian ...
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... expansion of PROVENT(R) Sleep Apnea Therapy in Limited ... Inc. a privately-held, medical device company, focused on ... the appointment of John McCutcheon as President and ... company also announced that current CEO Jeffrey Nugent ...
... Group (OTC Bulletin Board: SNBP) is pleased to ... Director of Marketing.Ms. Tan joins Sinobiopharma from Organon ... China-based Unit Marketing Director for Organon, which was ... Tan held senior marketing management roles at China ...
... Kiadis,Pharma reported preliminary clinical data on ATIR(TM) ... Data was presented by the,company,s principal investigator ... Symposium at the Annual European Bone Marrow ... March 30, 2009. Only the 6,highest ranked ...
Cached Biology Technology:Ventus Medical Appoints John McCutcheon as President and CEO 2Sinobiopharma, Inc. Appoints New Director of Marketing 2Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations 2
(Date:9/2/2014)... through a U.S. suburb , Observations and mapping ... the hours and days after the August 24 earthquake ... earthquake caused so much damage in the region, according ... by the American Geophysical Union. , ... Places to Direct Our Curiosity , Selecting where ...
(Date:9/2/2014)... The Field Museum will present the prestigious Parker/Gentry Award ... commitment to biodiversity conservation awareness. The Parker/Gentry Award is ... individual, team or organization whose efforts have had a ... and whose actions can serve as a model to ... an environmental science and conservation news website that draws ...
(Date:9/2/2014)... In Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone ... discoveries of emblematic fossils from that area (for ... have found fossil insects in the French equivalent ... new species representing the oldest known water treader. ... equivalent Bavarian outcrops, fewer fossils have been obtained ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... marine animals find their way back to their birthplace to ... has mystified scientists for more than a century. But marine ... think they might finally have unraveled the secret. At ... read the magnetic field of their home area and "imprint" ...
... from the California Institute of Technology (Caltech) have created ... the first time, the connection between the configuration of ... More precisely, they showed that the muscular band--which ... a helix--is actually a sort of twisting highway along ...
... (ST. LOUIS): The Missouri Botanical Garden Press (MBG ... species of vascular plants for the Southern Cone region, ... Plantas Vasculares del Cono Sur (Catalogue of the Plants ... the plants of Argentina, southern Brazil, Chile, Paraguay and ...
Cached Biology News:No place like home: New theory for how salmon, sea turtles find their birthplace 2No place like home: New theory for how salmon, sea turtles find their birthplace 3Caltech scientists show function of helical band in heart 2Missouri Botanical Garden publishes first catalogue of plants of the Southern Cone 2
... label transfer is fast emerging as a ... and confirmation. Until now, only amino groups ... label transfer reagents such as our Sulfo-SBED. ... Mts-Atf-LC-Biotin, are exciting additions to the protein ...
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... transfer is fast emerging as a powerful ... confirmation. Until now, only amino groups have ... transfer reagents such as our Sulfo-SBED. Sulfhydryl-reactive ... are exciting additions to the protein interaction ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
Biology Products: